Cargando…

Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer

PURPOSE: Data are limited on programmed death ligand 1 (PD-L1) expression in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We retrospectively evaluated the relationship between PD-L1 expression and recurrence-free survival (RFS) and overall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Jong Ho, Zhou, Wei, Choi, Yoon-La, Sun, Jong-Mu, Choi, Hyejoo, Kim, Tae-Eun, Dolled-Filhart, Marisa, Emancipator, Kenneth, Rutkowski, Mary Anne, Kim, Jhingook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784638/ https://www.ncbi.nlm.nih.gov/pubmed/28301925 http://dx.doi.org/10.4143/crt.2016.591

Ejemplares similares

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer
por: Roach, Charlotte, et al.
Publicado: (2016)

PD-L1 Expression and Survival among Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy()
por: Sorensen, Steffen Filskov, et al.
Publicado: (2016)

Quantitative Assessment of Tissue Biomarkers and Construction of a Model to Predict Outcome in Breast Cancer Using Multiple Imputation
por: Emerson, John W., et al.
Publicado: (2008)

The High Proportion of Discordant EGFR Mutations among Multiple Lung Tumors
por: Lee, Hyunwoo, et al.
Publicado: (2022)

Computational and Bioinformatics Frameworks for Next-Generation Whole Exome and Genome Sequencing
por: Dolled-Filhart, Marisa P., et al.
Publicado: (2013)

Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer
por: Kim, Tae-Jung, et al.
Publicado: (2017)

Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR
por: Ha, Sang Yun, et al.
Publicado: (2015)

Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications
por: Vainer, Gilad, et al.
Publicado: (2023)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2013)

Dysregulation of T(FH)-B-T(RM) lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer
por: Cho, Jae-Won, et al.
Publicado: (2021)

The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab
por: Shin, Jung Won, et al.
Publicado: (2019)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2019)

Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M
por: So, Kwang Sup, et al.
Publicado: (2014)

PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
por: Bai, Yuchen, et al.
Publicado: (2018)

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR ‐mutant non‐small cell lung cancer
por: Lei, Si‐Yu, et al.
Publicado: (2023)

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
por: Yoo, Kwai Han, et al.
Publicado: (2019)

Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
por: Kwon, Byoung Soo, et al.
Publicado: (2017)

Predictors of survival in patients who underwent video‐assisted thoracic surgery talc pleurodesis for malignant pleural effusion
por: Yoon, Dong Woog, et al.
Publicado: (2016)

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma
por: Koh, Young Wha, et al.
Publicado: (2023)

BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level
por: Kim, Ji Hye, et al.
Publicado: (2021)

Corrigendum: Circulating Aneuploid Cells Detected in the Blood of Patients with Infectious Lung Diseases
por: Kim, Hongsun, et al.
Publicado: (2017)

Circulating Aneuploid Cells Detected in the Blood of Patients with Infectious Lung Diseases
por: Kim, Hongsun, et al.
Publicado: (2017)

Efficacy of nano‐particulated, water‐soluble erlotinib against intracranial metastases of EGFR‐mutant lung cancer
por: Kim, Dong Ha, et al.
Publicado: (2018)

Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
por: To, Kenneth K. W., et al.
Publicado: (2021)

Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis
por: Hyun, Dong-gon, et al.
Publicado: (2020)

The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation
por: Lee, Youngjoo, et al.
Publicado: (2016)

Pneumonectomy for Clinical Stage I Non-Small Cell Lung Cancer in Elderly Patients over 70 Years of Age
por: Kim, Tae Ho, et al.
Publicado: (2015)

PDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applications
por: Jung, Hae-Yun, et al.
Publicado: (2020)

Single LED, Single PD-Based Adaptive Bayesian Tracking Method
por: Kim, Duckyong, et al.
Publicado: (2022)

Computational Design of Binding Proteins to EGFR Domain II
por: Choi, Yoon Sup, et al.
Publicado: (2014)

EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
por: Suh, Koung Jin, et al.
Publicado: (2017)

Quantitative CT Variables Enabling Response Prediction in Neoadjuvant Therapy with EGFR-TKIs: Are They Different from Those in Neoadjuvant Concurrent Chemoradiotherapy?
por: Chong, Yousun, et al.
Publicado: (2014)

Intensive care unit (ICU) readmission after major lung resection: Prevalence, patterns, and mortality
por: Jung, Jae Jun, et al.
Publicado: (2016)

Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach
por: Yoon, Hyun Jung, et al.
Publicado: (2015)

Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer
por: Yoon, Dong Woog, et al.
Publicado: (2022)

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
por: Gualberto, A, et al.
Publicado: (2011)

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
por: Gualberto, A, et al.
Publicado: (2012)

Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
por: Lee, Seung Eun, et al.
Publicado: (2019)

Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors
por: Kim, Jehun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j6s4rsllq346h7ns7e9j61avnn